National Immunobiological Company (Nacimbio)
A pharmaceutical holding company that develops and manufactures immunobiological drugs
A pharmaceutical holding company that develops, manufactures, and sells immunobiological drugs.
The company's mission is to promote the development of the Russian immunobiological industry and ensure the country's independence in the area of manufacturing and sales of immunobiological drugs, the lack of production of which in the Russian Federation constitutes a threat to national security in the field of health.
The company's General Director is Andrey Yuryevich Zagorsky.
Nacimbio was established by the State Corporation Rostec in 2013 in order to develop the production of immunobiological drugs that are crucial for the country's security. For this, the holding company was granted shares in two pharmaceutical manufacturers – JSC Sintez, a Kurgan-based top-10 Russian pharmaceutical plant in terms of the production volume, and LLC FORT – a full-cycle state-of-the-art research and production complex based in Ryazan Region. Later, Nacimbo was designated as a single executive body of the largest domestic immunobiological drugs manufacturer NPO Microgen.
The total staff of all of the holding company's entities is currently over 8 thousand people.
The company is one of the major players on the Russian pharmaceuticalом market: its total annual manufacturing output from the three facilities exceeds 250 million packages of medicinal products. The company's development is proceeding along the following key vectors: vaccines and toxoids that fit the current and any future National Vaccination Schedule; blood products; bacteriophages; allergens and allergoids.
The holding company and its entities contribute to the national immunobiological security by supplying nearly 90% of all vaccines required for the National Vaccination Schedule (by volume), bacteriophages for emergency prevention in disaster areas, and vaccines used for epidemiological indications - including tick-borne encephalitis, rabies, etc. As a single supplier, Nacimbio also promotes the expansion of influenza vaccinations, increasing their vaccine production and supply year after year. For example, in 2017-2018, in the course of the national campaign during the influenza and common cold season, Nacimbio supplied the government with more than 62.3 million doses that have been produced entirely from the Russian-made vaccine raw materials. This is 4 million doses more than the year before.
One of Nacimbio's strategic goals is to ensure the domestic production of new vaccines. As part of implementing various technology transfer projects in cooperation with foreign companies, Natsimbio plans to manufacture innovative vaccines, the production of which does not currently exist in the Russian Federation. Specifically, agreements have been signed and are in force between FORT and the American company MSD to establish domestic production of vaccines against rotavirus infection, chickenpox, and HPV, as well as between FORT and PharmAid Ltd (a joint venture with Ishvan Pharmaceutical Ltd) and the Indian Serum Institute of India on transferring the rotavirus vaccine production technology.
The holding company's product portfolio contains over 300 generic pharmaceutical products.
NPO Microgen is a developer of unique locally-manufactured medical drugs. Among them are vaccines against such highly contagious infectious diseases as measles, rubella, influenza, and several others. The company also manufactures the only domestic type A botulinum toxin, which is sold under the brand name Relatox, and a line of blood products – immunoglobulins, albumin, combined preparations of bacteriophages, and many others.
Kurgan-based Sintez is the leading domestic antibiotics manufacturer, and FORT produces a split influenza vaccine Ultrix® that meets all of the WHO recommendations. In 2019, FORT launched its innovative quadrivalent influenza vaccine Ultrix® Quadri.
Design and innovation
Nacimbio entities hold a vast portfolio of drug candidates at various stages of development. Specifically, a clinical trial is currently underway to explore the potential expansion of indications for using Relatox in treating neurological conditions. New bacteriophages have been developed and are being studied, and much attention is being paid to vaccines: the third phase of the rotavirus infection vaccine clinical trials has been completed; a combined vaccine Vactrivir for the prevention of measles, rubella, and mumps is awaiting registration.
In 2019, the first five-component combined vaccine against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae was approved for use in Russia.